Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.
Low cost technology – Ability to price Aquila products at same price as veterinarians pay today for an inferior product
Ability to work with any industry standard diagnostic instrument – Aquila is not building a diagnostic instrument: we are agnostic to instrument providing the customer with a wide variety of instrument options depending upon budget and requirements.
Patents on Aquila hydrogel – Strong patents in place in a technology where such patents are extremely difficult to achieve
Ability to work with “dirty” samples – Aquila’s patented hydrogel provides a significant and sustainable competitive advantage with its unmatched ability to work with “dirty” samples such as milk and feces.
Simple or no DNA extraction required from sample – Minimizes or eliminates step when compared to conventional PCR technology. Lowers cost and time to perform test.
Brent James, CEO, B.Comm UBC; MBA Sloan School MIT
Brent James has a 30-year history of accomplishments in the high tech field including co-founding a company (MDSI) that went public on NASDAQ, and being the turn-around CEO of a company (Abebooks.com), which was sold to Amazon.
Dr. Jason Acker, Co-Founder & CTO; BSc, MSc, MBA, PhD
Dr.Jason Acker, Co-Founder and Chief Technology Officer, brings more than 15 years of experience with multinational pharmaceutical and biotechnology companies in Canada, USA, Singapore and the U.K. Jason also managed interdisciplinary teams at the University of Alberta, Canadian Blood Services, and Harvard Medical School.
David Alton, Co-Founder & COO; MBA
David Alton co-Founder and Chief Operating Officer of Aquila, has extensive experience in the micro and nano technology sectors, research management and company start-ups